Skip to content

Study · In vitro (cells) · 2020

5 results

An engineered non-erythropoietic erythropoietin-derived peptide, ARA290, attenuates doxorubicin induced genotoxicity and oxidative stress.

Shokrzadeh M, Etebari M, Ghassemi-Barghi N

Toxicology in vitro : an international journal published in association with BIBRA23 Apr 2020Cited by 15 (Europe PMC)

PMID32335150 (opens in a new tab)DOI10.1016/j.tiv.2020.104864 (opens in a new tab)PepBankPUB-32335150
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Efficacy outcome

    In HepG2, HGF and stem cell lines, ARA290 pretreatment significantly reduced the percentage of tail DNA induced by doxorubicin.

    In plain wordsIn lab cells, ARA290 reduced the DNA damage caused by the cancer drug doxorubicin, compared with doxorubicin alone.

    Peptide
    Cibinetide (ARA-290)
    Outcome
    DecreaseDNA in comet tail induced by doxorubicin
    Study

    n: not reported in source

    HepG2, HGF and stem cell lines pretreated with ARA290 before doxorubicin (1 µM)
    Comparator
    Doxorubicin without ARA290
    Outcome group
    Cell viability and death · Whole body
    Studied dose
    50-400 nMAs given in this study.

    Source sentences

    Summary
    AR290 significantly reduced the percentage of DNA in tail
    2 context sentences
    Summary · context
    The genoprotective effect of ARA290 on DOX-induced toxicity in three cell line (HepG2, HGF & Stem cell) were assessed.
    Summary · context
    Cells were treated with ARA290 (50-400 nM) and DOX (1 μM) in pretreatment condition.
  2. 02LabIn vitro (cells)Efficacy outcome

    In HepG2, HGF and stem cell lines, ARA290 pretreatment significantly reduced the frequency of micronuclei induced by doxorubicin.

    In plain wordsIn lab cells, ARA290 reduced a marker of chromosome damage caused by doxorubicin, compared with doxorubicin alone.

    Peptide
    Cibinetide (ARA-290)
    Outcome
    DecreaseMicronuclei frequency induced by doxorubicin
    Study

    n: not reported in source

    HepG2, HGF and stem cell lines pretreated with ARA290 before doxorubicin (1 µM)
    Comparator
    Doxorubicin without ARA290
    Outcome group
    Cell viability and death · Whole body
    Studied dose
    50-400 nMAs given in this study.

    Source sentences

    Summary
    the frequency of micronuclei induced by DOX.
    2 context sentences
    Summary · context
    The genoprotective effect of ARA290 on DOX-induced toxicity in three cell line (HepG2, HGF & Stem cell) were assessed.
    Summary · context
    Cells were treated with ARA290 (50-400 nM) and DOX (1 μM) in pretreatment condition.
  3. 03LabIn vitro (cells)Efficacy outcome

    In HepG2, HGF and stem cell lines, ARA290 markedly attenuated doxorubicin-induced oxidative stress.

    In plain wordsIn lab cells, ARA290 clearly reduced the oxidative stress caused by doxorubicin, compared with doxorubicin alone.

    Peptide
    Cibinetide (ARA-290)
    Outcome
    DecreaseDoxorubicin-induced oxidative stress
    Study

    n: not reported in source

    HepG2, HGF and stem cell lines pretreated with ARA290 before doxorubicin (1 µM)
    Comparator
    Doxorubicin without ARA290
    Outcome group
    Cell viability and death · Whole body
    Studied dose
    50-400 nMAs given in this study.

    Source sentences

    Summary
    ARA290 markedly attenuated DOX induced oxidative stress
    2 context sentences
    Summary · context
    The genoprotective effect of ARA290 on DOX-induced toxicity in three cell line (HepG2, HGF & Stem cell) were assessed.
    Summary · context
    Cells were treated with ARA290 (50-400 nM) and DOX (1 μM) in pretreatment condition.
  4. 04LabIn vitro (cells)Efficacy outcome

    In HepG2, HGF and stem cell lines, ARA290 protected against doxorubicin-induced inflammation.

    In plain wordsIn lab cells, ARA290 protected against inflammation caused by doxorubicin, compared with doxorubicin alone.

    Peptide
    Cibinetide (ARA-290)
    Outcome
    DecreaseDoxorubicin-induced inflammation
    Study

    n: not reported in source

    HepG2, HGF and stem cell lines pretreated with ARA290 before doxorubicin (1 µM)
    Comparator
    Doxorubicin without ARA290
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    50-400 nMAs given in this study.

    Source sentences

    Summary
    protected against DOX induced inflammation and apoptotic cell death
    2 context sentences
    Summary · context
    The genoprotective effect of ARA290 on DOX-induced toxicity in three cell line (HepG2, HGF & Stem cell) were assessed.
    Summary · context
    Cells were treated with ARA290 (50-400 nM) and DOX (1 μM) in pretreatment condition.
  5. 05LabIn vitro (cells)Efficacy outcome

    In HepG2, HGF and stem cell lines, ARA290 protected against doxorubicin-induced apoptotic cell death.

    In plain wordsIn lab cells, ARA290 protected against cell death caused by doxorubicin, compared with doxorubicin alone.

    Peptide
    Cibinetide (ARA-290)
    Outcome
    DecreaseDoxorubicin-induced apoptotic cell death
    Study

    n: not reported in source

    HepG2, HGF and stem cell lines pretreated with ARA290 before doxorubicin (1 µM)
    Comparator
    Doxorubicin without ARA290
    Outcome group
    Cell viability and death · Whole body
    Studied dose
    50-400 nMAs given in this study.

    Source sentences

    Summary
    protected against DOX induced inflammation and apoptotic cell death
    2 context sentences
    Summary · context
    The genoprotective effect of ARA290 on DOX-induced toxicity in three cell line (HepG2, HGF & Stem cell) were assessed.
    Summary · context
    Cells were treated with ARA290 (50-400 nM) and DOX (1 μM) in pretreatment condition.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 19:08 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.